All News
Alzheon updates on precision medicine approach to treating AD
The American biotech firm Alzheon has unveiled data being presented at the Alzheimer’s Association International Conference (AAIC), in London. The company is conducting a Phase III [...]
Alzheon Presents New Data for Lead Candidate ALZ-801 on Novel MOA and Long- Term Clinical Efficacy at the Alzheimer’s Association International Conference
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for Precision Medicine Approach for ALZ-801 Targeting APOE4 Carriers FRAMINGHAM, [...]
Alzheon says data backs potential of Alzheimer’s candidate
US biotech points to new analysis of phase III results for tramiprosate Four years ago, US biotech Alzheon took a gamble on Alzheimer's candidate tramiprosate, thinking [...]
Alzheon to Present Novel Molecular Mechanism of Action and Long Term Clinical Efficacy Data for Lead Candidate ALZ-801 at the Alzheimer’s Association International Conference
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for Precision Medicine Approach for ALZ-801 FRAMINGHAM, Mass., June 22, [...]
Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients at the Mild Stage of Alzheimer’s Disease; Clinical Effects Suggest Disease Modification Potential and Align with Preclinical Effects on Beta Amyloid Oligomer Formation
Analyses from Phase 3 Studies Published in The Journal of the Prevention of Alzheimer’s Disease Show Strongest Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild AD [...]
Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013. This research and development has [...]